InsidersTradesSigma
Follow the JOINT Corp stock price and the full directors' dealings record of the company, a publicly traded company based in United States. Shares are quoted on the US market, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, JOINT Corp has recorded 53 reports. Market capitalisation: €119.4m. The latest transaction was reported on 12 June 2026 (Retenue fiscale). Among the most active insiders: JOBSON CHARLES E. Every trade is free.
53
Insider Decl.
n/a
Thresholds
€5m
16 ops.
Buy Volume
€10m
14 ops.
Sell Volume
29Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 13,769 of 29,064 companies
53.4
score / 100
Value44
Quality63
FCF yld0.3%
Earn yld2.4%
EV/EBITDA·
ROE11%
Gross mgn80%
Net mgn5.3%
Debt/EBITDA2.5x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 12 June 2026
Declarations53 total
1,392 sharesCommon StockSEC:0001551611-26-000006:0
127,676 shares@ US$8.570.79% mcap100.0% of flowCommonSEC:0001214659-26-006221:0
Canonical exit: 10 Aug 2026 (T+90)
73,484 shares0Common StockSEC:0002040461-26-000003:0
28,301 shares0Common StockSEC:0001551611-26-000003:0
15,397 shares@ US$8.507.8% of flowCommonSEC:0001214659-26-002092:0
Canonical exit: 13 May 2026 (T+90)
448 shares@ US$8.700.2% of flowCommonSEC:0001214659-26-001739:0
Canonical exit: 12 May 2026 (T+90)
16,753 shares@ US$10.0010.1% of flowCommonSEC:0001214659-26-000898:0
Canonical exit: 23 Apr 2026 (T+90)
5,240 shares@ US$8.892.8% of flowCommonSEC:0001214659-26-000288:0
Canonical exit: 6 Apr 2026 (T+90)
11 shares@ US$8.700.0% of flowCommonSEC:0001214659-26-000129:0
Canonical exit: 31 Mar 2026 (T+90)
10,000 shares@ US$8.416.5% of flowCommonSEC:0001214659-25-017802:0
Canonical exit: 5 Mar 2026 (T+90)
13,000 shares@ US$8.418.5% of flowCommon StockSEC:0001214659-25-017579:0
Canonical exit: 1 Mar 2026 (T+90)
2,081 shares@ US$8.431.6% of flowCommon StockSEC:0001214659-25-017240:0
Canonical exit: 23 Feb 2026 (T+90)
10,000 shares@ US$10.408239.9% of flowCommon StockSEC:0000950170-25-111000:0
Canonical exit: 18 Nov 2025 (T+90)
14,388 shares@ US$10.879360.1% of flowCommon StockSEC:0000950170-25-110202:0
Canonical exit: 13 Nov 2025 (T+90)
4,995 shares0Common StockSEC:0000950170-25-097937:0
19,984 shares0Common StockSEC:0000950170-25-085520:0
4,849 shares0Common StockSEC:0000950170-25-082517:0
6,593 shares@ US$13.86421.3% of flowCommon Stock, $0.001 Par Value Per ShareSEC:0000921895-22-002003:0
Canonical exit: 11 Sept 2022 (T+90)
3,170 shares0Common StockSEC:0001171843-22-004048:0
3,170 shares0Common StockSEC:0001171843-22-004049:0
3,170 shares0Common StockSEC:0001171843-22-004044:0
3,170 shares0Common StockSEC:0001171843-22-004046:0
3,170 shares0Common StockSEC:0001171843-22-004045:0
22,187 shares@ US$14.97624.7% of flowCommon Stock, $0.001 Par Value Per ShareSEC:0000921895-22-001809:0
Canonical exit: 22 Aug 2022 (T+90)
25 of 53 declarations
关于 JOINT Corp
JOINT Corp.（股票代码：JYNT）是一家在美国纳斯达克上市的美国公司。它通过 The Joint Chiropractic® 网络在脊椎治疗领域运营，结合了诊所运营、管理服务和特许经营。对于法语投资者而言，其投资案例最好理解为一种零售医疗模式：一种以便利性、透明定价和简化患者体验为核心的面向消费者的健康和疼痛缓解服务。该公司总部位于亚利桑那州斯科茨代尔，其品牌主张围绕着无需预约、无保险复杂性以及标准化护理模式，这使其有别于传统的脊椎治疗诊所。（[ir.thejoint.com](https://ir.thejoint.com/company-information?utm_source=openai)) 这家现代公司表示，它于 2010 年 3 月收购了其前身，标志着其当前增长阶段的开始。自那时以来，The Joint Corp. 已从一个小型基础扩展成为一个全国性平台。在其 SEC 文件中，该公司报告称，截至 2024 年 12 月 31 日，有 967 家诊所投入运营，另有已售出但尚未开发的特许经营许可证。公司资料还指出，该网络覆盖 43 个州，每年有超过 14 million 次患者就诊。这种规模很重要，因为随着网络密度的提高和品牌知名度的增强，其商业模式变得更具吸引力。（[sec.gov](https://www.sec.gov/Archives/edgar/data/1612630/000161263025000033/jynt-20241231.htm?utm_source=openai)) 从竞争角度来看，JOINT Corp. 似乎是美国脊椎治疗领域的明显规模领导者。管理层表示，该品牌比其最接近的脊椎治疗连锁竞争对手大约大六倍，这突显了其在一个仍分散的类别中的领先地位。其核心服务包括脊椎调整、持续健康护理以及通过标准化诊所形式提供的相关患者治疗计划。该公司的循环会员模式和无需预约的方式旨在使护理更经济实惠、更易于获得，同时支持重复就诊和更广泛的消费群体。（[sec.gov](https://www.sec.gov/Archives/edgar/data/1612630/000162828025012702/jynt-20241231.htm?utm_source=openai)) 最近的发展主要集中在战略简化和盈利能力提升上。2024 年，该公司继续朝着“纯特许经营商”结构推进，重新特许经营了某些公司诊所，并减少了直接运营风险。2025 年初，管理层表示已开始执行旨在加强核心业务、重振增长以及提高诊所和公司层面盈利能力的举措。这一信息对投资者很重要，因为它标志着从“不惜一切代价增长”的扩张模式向更具纪律性的特许经营主导运营结构的转变。（[sec.gov](https://www.sec.gov/Archives/edgar/data/1612630/000162828025012702/jynt-20241231.htm?utm_source=openai))
